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Introduction The use of statins for primary prevention of cardiovascular disease (CVD) is increasing in older 18 
adults. Nonetheless, good clinical evidence for the safety and tolerability of statins in this population is limited.  19 
Objective We aimed to evaluate the safety and tolerability of statins in older adults without overt CVD, with 20 
focus on statin-related muscle symptoms. 21 
Methods Double-blinded randomised controlled trials (RCTs) of statins published before January 2012 were 22 
identified from a Cochrane review updated to 2012. Trials published between January 2012 to July 2018 were 23 
identified through the CENTRAL, MEDLINE and EMBASE databases. Eligible trials were limited to those 24 
including individuals aged ≥ 65 years without overt CVD, who were followed for at least one year. Trials should 25 
report at least one of the outcomes of interest. Pooled relative risk (RR) estimates and 95% confidence intervals 26 
(CIs) were calculated using the random-effects models.  27 
Results Eleven trials including 18,192 participants were identified (mean age 73.7 years; 43% females). 28 
Compared with placebo, statins neither increase the risks of muscle-related symptoms (RR 1.01; 95% CI 0.90 to 29 
1.12), total adverse events (AEs) and serious AEs nor lead to more total permanent treatment discontinuations and 30 
discontinuations due to AEs or specifically due to muscle-related symptoms. No evidence of heterogeneity was 31 
observed in any of these outcomes.  32 
Conclusions This meta-analysis of RCTs found no excess incidence of muscle-related symptoms, total AEs, 33 
serious AEs and treatment discontinuations attributable to statin compared with placebo among older adults 34 
without CVD.  35 
Keywords Hydroxymethylglutaryl-CoA Reductase Inhibitors; Safety; Primary prevention; Aged; Meta-Analysis   36 
Key Points 37 
• The present meta-analysis of randomised controlled trials systematically evaluated the safety and 38 
tolerability of statins in older adults without overt cardiovascular disease (CVD).  39 
• This meta-analysis found no significant difference in muscle-related symptoms, any adverse event and 40 
any serious adverse event between statin and placebo groups in older adults without CVD. 41 
• This meta-analysis found no excess incidence of total treatment discontinuations and AE-related 42 
treatment discontinuations of statins relative to placebo in older adults without CVD. 43 
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1 Introduction 45 
Use of statins for the secondary prevention of cardiovascular disease (CVD) in older adults, defined as individuals 46 
aged 65 years and older, has been well-acknowledged and supported by a strong body of evidence [1]. However, 47 
for primary prevention with statins, recommendations in clinical guidelines from different countries are 48 
inconsistent in adults aged 65-75 years and are generally lacking in those aged 75 years and older, who have been 49 
largely underrepresented in clinical trials [2, 3]. Despite this, there has been a marked increase of statin 50 
prescriptions for primary prevention in older adults over the past decade, owing to their higher disease burden and 51 
poorer outcomes following a first cardiovascular event [4-6]. The widespread use of statins in this subpopulation 52 
has raised great concerns about potential statin-related risks, upon which the clinical trial evidence is weak and 53 
limited [7]. 54 
Compared with younger adults, older adults seem to be more susceptible and less resilient to statin-related 55 
adverse events (AEs) and drug-drug interactions owing to decreased physiologic reserve, multiple morbidities and 56 
polypharmacy [8, 9]. Statin-associated muscle symptoms (SAMS) are the most commonly reported AEs in clinical 57 
practice, occurring in approximately 7% to 29% of statin-users and contributing to up to 75% of treatment 58 
discontinuations of statins within two years of treatment initiation [10]. The clinical presentation of SAMS is 59 
highly heterogeneous, mainly characterised by muscle pain or aches (myalgia), muscle weakness, stiffness and 60 
cramp, with normal or slightly elevated creatine kinase (CK) concentrations [10]. For older adults, SAMS may 61 
substantially impact their independence and quality of life by exacerbating physical deconditioning and frailty 62 
[11]. Two rare and severe forms of SAMS - myopathy (defined as muscle symptoms with CK >10 × the upper 63 
limit of normal [ULN]) and rhabdomyolysis (defined as muscle symptoms with CK >40 × ULN when 64 
accompanied with renal impairment and/or myoglobinuria) are devastating and potentially life-threatening [10]. 65 
In real-world populations, it was estimated that the myopathy and rhabdomyolysis occur in 5 and 1.6 patients per 66 
100,000 person-years, respectively [12].  67 
The high incidence and prevalence of SAMS and other statin-related AEs were mainly observed in non-68 
randomised scenarios, including observational studies, patient registries and routine clinical settings [13]. 69 
However, owing to the lack of a comparator in these contexts, any relation between reported AEs and statin use 70 
can only be seen as associative. In contrast, results yielded using data from randomised controlled trials (RCTs) 71 
that enable the establishment of causal relations, should provide more reliable evidence of actual statin attributable 72 
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AEs. Therefore, we conducted a systematic review and meta-analysis of RCTs to comprehensively evaluate the 73 
safety and tolerability of statins versus placebo in primary prevention in older adults, with a focus on the risk of 74 
SAMS. We also assessed the incidence of total AEs, serious AEs (SAEs), and permanent treatment 75 
discontinuations between statin and placebo groups, as these outcomes present the general safety and tolerability 76 
profiles of a treatment.  77 
 78 
2 Methods 79 
2.1 Systematic Review Registration 80 
The study protocol has been previously registered (PROSPERO: CRD42017058436) and published [14]. This 81 
systematic review and meta-analysis was reported in accordance with the Preferred Reporting Items for 82 
Systematic Reviews and Meta-Analyses (PRISMA) method [15].  83 
 84 
2.2 Data Sources and Study Selection  85 
We selected eligible trials published before January 2012 from the reference lists of a published Cochrane 86 
systematic review (updated to 2012) of RCTs of statins including adults without established CVD [16]. A new 87 
search using the CENTRAL, MEDLINE and EMBASE databases was conducted to identify eligible trials 88 
published between January 2012 and July 2018. The full search strategy was outlined in our protocol [14]. No 89 
language restrictions were applied. We also manually searched relevant reviews and the reference lists of eligible 90 
articles to supplement the electronic search. Two reviewers (Z.Z., L.A.) screened the titles and abstracts of articles 91 
independently against the selection criteria. The full text of articles that potentially met the eligibility criteria were 92 
retrieved. Discrepancies were resolved by discussion with a third reviewer (M.N.). 93 
 94 
2.3 Selection Criteria 95 
We included studies that met the following criteria: 1) double-blind RCTs of statins versus placebo with at least 96 
one-year follow-up and; 2) reporting at least one outcome of interest (defined below in section 2.4 Outcomes) in 97 
(subgroup of) participants aged 65 years or more without overt CVD.   98 
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We also excluded studies that 1) targeted participants with certain pre-existing conditions including cancer, 99 
hypothyroidism, acute infection, chronic kidney disease, human immunodeficiency virus infection, post-100 
transplantation, or any other acute illness, which may increase the risk of AEs [17]; 2) studied cerivastatin, which 101 
was withdrawn from the market in 2001 or; 3) studied a combination of statins with any other lipid-lowering 102 
medication as the study treatment.  103 
 104 
2.4 Outcomes  105 
The primary outcome was adverse muscle symptoms including myalgia, muscle weakness, stiffness, tenderness 106 
and cramp (myopathy and rhabdomyolysis were not included) [10].  107 
Other outcomes included myopathy, rhabdomyolysis, any AE (refers to the AEs recorded in the original trial; 108 
we did not exclude adverse muscle symptoms, myopathy and rhabdomyolysis if these outcomes were counted as 109 
AEs in the original trial), any SAE (defined as adverse experiences that were considered serious including life-110 
threatening, causing death or a permanent disability or incapacity, resulting in or prolonging hospitalisation) [18], 111 
permanent treatment discontinuation of statins or placebo due to any reason, AEs or adverse muscle symptoms.  112 
 113 
2.5 Data Extraction and Quality Assessment 114 
Two reviewers (Z.Z., L.A.) independently extracted data using a predefined, standardised data extraction sheet. 115 
When trial outcome data was published in a form that corresponded to our age eligibility criteria (age ≥ 65 years) 116 
it was extracted directly from the publication in aggregate form. If there was no subgroup data provided for the 117 
over 65 age group, we requested individual patient data from the corresponding authors and/or pharmaceutical 118 
sponsors of the original trial and performed the appropriate analysis for that age group. The risk of bias of included 119 
trials was assessed using the Cochrane’s Risk of Bias Tool (RevMan Version 5.3.5, The Cochrane Collaboration) 120 
[19]. We assessed the overall risk of bias for each trial based on the judgement of each domain as high, low or 121 
unclear risk and rated it by the highest risk assigned across individual domains. We used the Grading of 122 
Recommendations Assessment, Development, and Evaluation (GRADE) approach to rate the quality of evidence 123 
for each outcome across all the trials as very low, low, moderate or high, with a ‘Summary of findings’ table 124 
created [20]. More details can be found in our published protocol [14]. 125 
 126 
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2.6 Data Synthesis and Analysis 127 
To account for a between-study variation in the effect sizes of an outcome, we employed the DerSimonian and 128 
Laird random-effects models to perform meta-analyses of outcomes (except for myopathy and rhabdomyolysis) 129 
[21]. Results of the analyses were presented as risk ratios (RRs) with 95% confidence intervals (95% CIs). We 130 
provided a narrative statement for myopathy and rhabdomyolysis as most included trials reported zero events of 131 
these two outcomes in both arms.  132 
Between-study heterogeneity was assessed using the I2 statistic [22]. I2 values of 0%-40%, 30%-60%, 50%-133 
90%, and 75%-100%  correspond to negligible, moderate, substantial and considerable heterogeneity, respectively 134 
[21]. Subgroup analyses were conducted for the primary outcome based on pre-specified factors including follow-135 
up duration ( <3-year, ≥ 3-year), the dose intensity of statins (standard, intensive, multiple) [23], and the solubility 136 
of statins (hydrophilic, lipophilic). As only nine trials reported the primary outcome, we were unable to assess 137 
publication bias using funnel plots and Egger’s regression test as planned [24]. A leave-one-out sensitivity analysis 138 
was conducted by iteratively removing one study at a time to assess the impact of every single study. Meta-139 
regression was not conducted to minimise the risk of false positives [25].  140 
All the analyses were conducted using R (Version R-3.5.1). All tests were 2-tailed. A p-value <0.05 was 141 
considered statistically significant. 142 
 143 
3 Results  144 
3.1 Trials Retrieved and Study Characteristics 145 
The trial selection flowchart is presented in Fig. 1. Of 9,751 citations identified initially by our new established 146 
search, 71 articles were retrieved for full review and two publications from one trial (Heart Outcomes Prevention 147 
Evaluation [HOPE]–3 trial [26]) met our eligibility criteria in the database search. However, this trial had a wider 148 
age-range criterion and was excluded later as separate data for older adults could not be obtained [27]. Ten RCTs 149 
selected from the Cochrane review and one from the manual search were included in the final analyses, with a 150 
total of 18,192 subjects included (mean age 73.7 years; 43% females; median follow-up 3.0 years).  151 
Fig. 1 Study selection process. HOPE-3 Heart Outcomes Prevention Evaluation-3, RCT randomised controlled 152 
trial. a: Trial by Bruckert et al. b: MRC/BHF (Medical Research Council/British Heart Foundation) Heart 153 
Protection study [28], HOPE-3 trial [26] and ACAPS (Asymptomatic Carotid Artery Plaque Study) trial [29]. 154 
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The characteristics of the included RCTs are summarised in Table 1. Trials conducted by Bruckert et al. and 155 
Chan et al. exclusively enrolled older adults without overt CVD [30, 31]. Data from 3 trials were derived from 156 
the post-hoc analyses of the primary trials [32-34].  Data from 4 trials were extracted from individual patient data 157 
[35-38]. Data from the PROSPER trial [39] were obtained from the meta-analysis by Teng et al. [40] and data 158 
from the ASCAPS-TexCAPS trial [41] were from the meta-analysis by Iwere et al [42].  159 
 160 
3.2 Risk of Bias and Quality of Evidence 161 
Results of the risk of bias assessment are presented in Fig. 2. In terms of the rating of methodological quality 162 
items across all included trials, half of the trials were rated as having an unclear risk of bias for the random 163 
sequence generation and for the allocation concealment. Most of the trials were rated as having an unclear or high 164 
risk for the item of ‘other bias’ because they were funded by pharmaceutical companies. For the remaining items, 165 
the majority of included trials were rated as having a low risk of bias. In terms of the methodological quality for 166 
each individual trial, eight trials (ASCAPS-TexCAPS 1998 [41], PROSPER 2002 [39], CARDS 2004 [34], 167 
PREVEND IT 2004 [37], ASPEN 2006 [38], Bone 2007 [36], METEOR 2007 [35] and ASCOT-LLA 2011 [32, 43]) 168 
were rated as having an unclear risk of bias, and three trials (Chan 1996, [31] Bruckert 2003, [30] JUPITER 2010 169 
[33, 44]) were rated as having a high risk of bias.  170 
Fig.2 Risk of bias’ summary (a) and graph (b): review author’s judgements about each methodological quality 171 
item presented as percentages across all included trials (a) and for each included trial (b)  172 
 173 
The quality of evidence applied for each outcome was summarised in the ‘Summary of findings’ table 174 
according to the GRADE approach (Supplementary Table. 1). The quality of evidence on adverse muscle 175 
symptoms, AEs, SAEs, permanent treatment discontinuations due to AEs and due to muscle-related symptoms 176 
was rated moderate and on myopathy, rhabdomyolysis and total permanent discontinuations was rated low. 177 
Supplementary Table 1. ‘Summary of findings’ generated by the GRADE [20] 178 
 179 
3.3 Adverse Muscle Symptoms  180 
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Nine trials with 7.7% (642/8346) of participants in the statin group versus 7.5% (622/8287) of participants in the 181 
placebo group reported adverse muscle symptoms. There was no significant difference in the risk of adverse 182 
muscle symptoms between the two groups (RR 1.01, 95% CI 0.90 to 1.12, p = 0.50, I2 = 1.1%) (Fig. 3).  183 
Fig. 3 Relative risks along with 95% confidence intervals of adverse muscle symptoms between the statin and 184 
placebo groups. CI confidence interval.   185 
 186 
3.4 Myopathy and rhabdomyolysis 187 
Seven trials with 0.06% (4/6724) of participants treated with statins versus 0.05% (3/6655) treated with placebo 188 
reported myopathy. Of seven trials with available data on rhabdomyolysis, only one case (1/7691) in the statin 189 
group and none (0/7617) in the placebo group were recorded. 190 
 191 
3.5 AE and SAE 192 
Six trials with 34.3% (581/1694) of participants treated with statins versus 30.0% (468/1560) treated with placebo 193 
reported AEs. Seven trials with 28.0% (2238/7989) of participants treated with statins versus 28.5% (2270/7958) 194 
treated with placebo reported SAEs. The risks of both AEs (6 trials; RR 0.99, 95% CI 0.95 to 1.04, p = 0.95, I2 = 195 
0.0%) and SAEs (RR 1.01, 95% CI 0.97 to 1.05, p = 0.89, I2 = 0.0%) did not differ significantly between statin 196 
and placebo (Fig. 4). 197 
 198 
3.6 Permanent Treatment Discontinuation  199 
There were no significant differences observed in the incidence of total permanent treatment discontinuations (6 200 
trials; RR 0.99, 95% CI 0.81 to 1.22, p = 0.81, I2 = 0.0%), permanent treatment discontinuations due to AEs (8 201 
trials; RR 1.05, 95% CI 0.83 to 1.33, p = 0.59, I2 = 0.0%) and due to adverse muscle symptoms (6 trials; RR 1.17, 202 
95% CI 0.64 to 2.14, p = 0.75, I2 = 0.0%) of statins versus placebo (Fig. 4).  203 
Fig. 4 Relative risks along with 95% confidence intervals of adverse events, serious adverse events, total 204 
permanent discontinuations, discontinuations due to adverse events and adverse muscle symptoms. AE adverse 205 
event, CI confidence interval, MS muscle-related symptoms. 206 
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 3.7 Subgroup analyses 208 
The results of subgroup analyses suggest that our primary result was consistent regardless of the solubility and 209 
dosing of statins assigned and the length of follow-up duration of trials (Supplementary Fig. 1, 2, 3). 210 
Supplementary Fig. 1 Subgroup analysis of adverse muscle symptoms in terms of the solubility of statins. CI 211 
confidence interval 212 
Supplementary Fig. 2 Subgroup analysis of adverse muscle symptoms in terms of the dose intensity of statins. 213 
CI confidence interval 214 
Supplementary Fig. 3 Subgroup analysis of adverse muscle symptoms in terms of the length of follow-up of 215 
trials. CI confidence interval 216 
 217 
3.8 Sensitivity analysis 218 
The results yielded by the leave-one-out sensitivity analysis were consistent with the primary result, indicating 219 
that our primary finding was not driven by any single study (Supplementary Fig. 4).  220 
Supplementary Fig. 4 Leave-one-out sensitivity analysis for the primary outcome. RR relative risk, CI confidence 221 
interval 222 
 223 
4. Discussion 224 
4.1 Principal Findings   225 
In this meta-analysis of eleven RCTs, we found no evidence of an excess incidence of adverse muscle symptoms, 226 
AEs and SAEs attributable to statin compared to placebo in older adults without overt CVD. For myopathy and 227 
rhabdomyolysis, incidence rates were extremely low in both statin and placebo groups. Additionally, the incidence 228 
of total permanent discontinuations and of permanent discontinuations due to AEs or adverse muscle symptoms 229 
were not significantly different between statin and placebo groups. Our study findings supplement the current 230 
evidence base regarding the safety and tolerability of statin use in older adults in the primary prevention setting.  231 
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We did not evaluate the risk of other purported statin-related AEs such as diabetes and haemorrhagic stroke, 232 
as they may only emerge after long-term statin exposure in large numbers of patients [45]. In a cohort study of 233 
22,340 older adults, 45% discontinued statins within one year of treatment initiation [46]. It therefore seems likely 234 
that participants may be more concerned about the more immediate side effects of statins such as SAMS. 235 
 236 
4.2 Comparison with Other Studies and Possible Explanations 237 
Prior to our study, a meta-analysis by Teng et al [40] using published data from statin trials showed no increased 238 
risk of myalgias, SAEs and AE-related treatment discontinuations associated with statin use versus placebo/usual 239 
care in older adults without CVD. Our study updated their study findings by adding new data from four clinical 240 
trials, applying stringent selection criteria, and looking into additional safety-related outcomes which are 241 
clinically-relevant. Another meta-analysis of RCTs of older adults with and without CVD history by Iwere et al 242 
[42] also showed no significant difference in the risks of muscle-related symptoms and AE-related treatment 243 
discontinuations between statin and placebo/usual care groups.  244 
Whilst our study findings were consistent with previous meta-analyses of RCTs, they do not concur with the 245 
high prevalence of SAMS and other statin-related AEs observed in routine clinical settings. In the absence of a 246 
comparator group in real-world scenarios, it is possible that patients and their health providers may misattribute 247 
symptoms to statins if that patient was currently taking statin drugs. Evidence for this is seen in a large cohort 248 
study in a routine care setting, in which more than 90% of statin-users who were re-challenged after suffering an 249 
AE could tolerate a statin long-term [47]. In fact, muscle complaints are frequently reported by older adults and 250 
the reasons can be diverse (i.e. sarcopenia, increased physical activity, diseases that lead to or increase the 251 
susceptibility to muscle problems, medications with known muscular toxicity) [10]. Such misattribution may 252 
prevent a substantial number of older adults from taking statins, and mean they forego potential cardiovascular 253 
benefits with more incident events as a consequence [10]. 254 
The “nocebo effect” may also provide some explanation for the higher prevalence of SAMS in real-world 255 
practice [48]. The ‘nocebo effect’ refers to the idea that subjective AEs such as aches and pain are due to patients’ 256 
expectations of harm from statin therapy, because of their awareness and concerns about possible statin-related 257 
side effects [49]. In fact, the misattribution bias and ‘nocebo effect’ (if participants believe they are taking statins 258 
whether or not they are) may also occur in RCTs. Despite this, they impact statin and placebo groups equally. 259 
Hence their presence will not distort the estimates of treatment effects. In this meta-analysis, the incidence of 260 
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adverse muscle symptoms was found to be similar between statin and placebo groups (7.7% vs. 7.5%), further 261 
indicating that the AEs observed in the statin group were not necessarily related to the study treatment.  262 
It is worth-noting that the generalisability of our study findings may be limited to routine clinical settings due 263 
to the inadequate representation of real-world populations. Participants within a clinical trial are more 264 
homogeneous than real-world populations, with regards to demographic, functional and clinical aspects. In this 265 
meta-analysis, most included trials involved predominantly white and older adults of age less than 80 years. 266 
Therefore, our study results may not apply to very old populations and other races or ethnicities. Trial participants 267 
also tend to be more motivated and to have better physical and psychological functioning, so that the risk of statin-268 
related AEs for these individuals is likely to be lower [50]. In view of this, evidence from clinical registries that 269 
reflect day-to-day clinical practice can be complementary to randomised evidence and provide some value for 270 
informing clinical decision-making, while also acknowledging the design limitations.  271 
4.3 Limitations 272 
Several limitations in this review need to be raised. Firstly, evidence quality of the outcomes in this review was 273 
rated from low to moderate. Therefore, the results should be interpreted with caution. Secondly, individual patient 274 
data from three identified trials [26, 28, 29] could not be obtained, which lowers the study power. Thirdly, a 275 
median follow-up of 3 years of included trials may limit study ability to assess the safety and tolerability of statins 276 
over the long-term. However, common and immediate side effects of statins such as SAMS are more likely to be 277 
clinically-concerning issues that were reported to contribute to a high rate of statin discontinuations within the 278 
early period (1-2 years) of treatment initiation [10]. Fourthly, all the included trials were industry-sponsored and 279 
therefore may be biased in favour of the sponsor’s drugs. However, this limitation is likely to be minimal as all 280 
the reported AEs were recorded by blinded personnel. Additionally, as seven included trials did not perform 281 
further subgroup analysis by age and participants’ mean age in three trials was unknown, we were unable to 282 
conduct a subgroup analysis or meta-regression to assess whether age increases the risk of statin-related AEs and 283 
the incidence of treatment discontinuations of statins. Moreover, some trials have a small sample size and 284 
unbalanced treatment arms, which may influence the accuracy of the results. While no heterogeneity was observed 285 
in the meta-analyses of all outcomes, the small study effect appeared to be negligible. Finally, the study results 286 
may have generalisability considerations for patients in routine clinical settings.  287 
 288 
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5. Conclusions  289 
In this meta-analysis of RCTs, we found no evidence of an excess incidence of adverse muscle symptoms, total 290 
AEs, SAEs and treatment discontinuations attributable to statin compared to placebo among older adults without 291 
CVD. As statin intolerance and discontinuation remain important and unresolved clinical issues, further evidence 292 
from high-quality RCTs that design priori to assess the safety and tolerability of statins in older adults without 293 
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Table 1 Baseline characteristics and outcomes reported of the included trials 
 
  


























Chan et al[31] 
 
1996 China 96 
(48/48) 
77 (≥65) 1.0 51 Pravastatina 
(15mg/d) 
Standard 5.27 Dietary 
(12) 





1998 U.S. 1416 
(715/701) 















75(70-82) 3.3 59 Pravastatina 
(40mg/d) 
Standard 3.80 Placebo 
(4) 










76(69-92) 1.0 75 Fluvastatin 
XLb 
(80mg/d) 









27   Pravastatina 
    (40mg/d) 
Standard 4.30 None No TPD, PD-AE 
 CARDS[34] 
 






Standard 3.06 Placebo 
(6) 
Yes MS,MY,RB, AE, 
SAE, PD-AE 
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ASCAPS-TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study; PROSPER: Pravastatin in Elderly Individuals at Risk of Vascular Disease; PREVEND IT: Prevention of Renal and 
Vascular Endstage Disease Intervention Trial; CARDS: Collaborative Atorvastatin Diabetes Study; ASPEN: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-
Dependent Diabetes Mellitus; METEOR: Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin; JUPITER: Justification for the Use of statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin; ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm; MS: Muscle-related symptoms MY: Myopathy; RB: Rhabdomyolysis; TPD: Total permanent 
discontinuation; PD-AE: Permanent discontinuation due to AEs; PD-MS: Permanent discontinuation due to muscle-related symptoms; HTN: Hypertension; NR: Not reported; a: Hydrophilic; b: Lipophilic; 
c: Patients with the history of angina were excluded; d: Median. 




























2006 14 countries 590c 
(309/281) 
69(65-78) 4 34 Atorvastatinb 
(10mg/d) 




Bone et al[36] 
 
2007 U.S. 129 
(100/29) 
69(65-78) 1 100 Atorvastatinb 
(10-80mg/d) 





2007 U.S. and Europe 81 
(58/23) 
NR (65-74) 1.8 77 Rosuvastatina 
40mg/d 
Intensive 3.99 None No MS,MY,RB,AE, 





























Standard 3.44 None Yes MS,RB, SAE, 
PD-AE,PD-MS 
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